Victory Capital Management
MLNT

Victory Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Victory Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,748
Closed -$7K – 3704
2019
Q3 		$7K Buy
+1,748
New +$6.3K ﹤0.01% 3390

Other funds holding MLNT

Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Victory Capital Management's MLNT Position: Q4 2019 in Review

Victory Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 1,748 shares — an estimated $7K sold.

Victory Capital Management first reported a position in MLNT in Q3 2019 and held it in 1 quarter. The position peaked at $7K in Q3 2019. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

  • Victory Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Victory Capital Management sold 1,748 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $7K.
  • Victory Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Victory Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $7K in Q3 2019.
  • 37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Victory Capital Management's 13F filing for Q4 2019, filed 4 Feb 2020.